Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in High-Risk Patients
2023-510564-12-00Phase 3Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of formoterol in postoperative respiratory complications (PRC) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: postoperative pulmonary complications at day 7. Planned start Oct 2024; status: authorised.
02
Drugs
formoterol
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on 2023-510564-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510564-12-00.